The Imbalance of Homeostasis in Neutrophil Extracellular Traps is Associated with Portal Vein Thrombosis in Patients with Decompensated Cirrhosis

Ming Han, Yujia Liu, Ying Cao, Yue Zhang, Yonghong Yan, Shuwei Deng, Xiaoxue Yuan, Huichun Xing, Yuan Huang, Liuluan ZhuJournal of Clinical and Translational Hepatology 2024 · DOI

TL;DR

This study reveals that an imbalance in "NET homeostasis"—where the formation of Neutrophil Extracellular Traps (NETs) outpaces their degradation by DNase—is a key driver and potential diagnostic marker for Portal Vein Thrombosis (PVT) in patients with advanced liver cirrhosis. Specifically, histone-DNA complexes emerged as a robust independent risk factor, offering a more sensitive way to detect dangerous blood clots than current standard imaging.

What Problem Does This Paper Address?

Portal Vein Thrombosis (PVT) is a frequent and life-threatening complication for patients with liver cirrhosis, occurring in up to 26% of cases (and 40% of those with liver cancer). When a clot blocks the portal vein, it spikes blood pressure in the liver, leading to intestinal death or internal bleeding.

The current "gold standard" for non-invasive diagnosis is ultrasound, but its sensitivity is often poor. There is a desperate need for reliable blood-based biomarkers that can catch these clots early. While researchers knew that NETs—web-like structures of DNA and proteins spat out by neutrophils to trap pathogens—play a role in clotting, it wasn't clear if the imbalance between their production and their cleanup (by the enzyme DNase) could serve as a clinical diagnostic tool in the context of chronic hepatitis B (CHB) and cirrhosis.

Methods

The researchers took a "homeostasis" approach, looking at both sides of the NET equation:

  1. Formation Markers: They measured cell-free DNA (cfDNA) and histone-DNA complexes in the plasma.
  2. Degradation Marker: They measured the activity of Deoxyribonuclease (DNase), the enzyme responsible for "chopping up" NETs once they've done their job.

They used a combination of:

  • ELISA and Fluorometric Assays to quantify these markers.
  • Logistic Regression to determine which factors independently predicted the presence of a clot.
  • ROC (Receiver Operating Characteristic) Curve Analysis to calculate the diagnostic accuracy (AUC) of these markers.

Datasets

The study utilized two distinct patient cohorts:

  • The Ditan Study (Discovery): 145 patients with CHB-related decompensated cirrhosis from Beijing Ditan Hospital.
  • The Changgung Study (Validation): 33 patients from Beijing Tsinghua Changgung Hospital used to verify if the findings held up in a different clinical setting.
  • Sub-groups: Patients were further categorized by Child-Pugh grade (liver disease severity) and the presence/absence of Hepatocellular Carcinoma (HCC).

Key Insights and Ideas

  • The "Cleanup" Failure: The most striking insight is that PVT isn't just caused by more NETs being made; it’s exacerbated by a failure to clear them. Patients with clots had significantly lower DNase activity, meaning the "biological webs" that trigger clotting were allowed to persist.
  • Histone-DNA is the "Smoking Gun": While cfDNA is a common marker for cell death, histone-DNA complexes were much more specific to PVT. In the Ditan study, histone-DNA levels were nearly 3 times higher in patients with clots.
  • Independence from Cancer: Biomarkers often become "noisy" in cancer patients. However, this NET imbalance remained a significant indicator of PVT regardless of whether the patient also had liver cancer (HCC).
  • Synergy in Markers: Combining histone-DNA, cfDNA, and DNase activity into a single model provided better diagnostic power than any single marker alone, suggesting that the entire "homeostatic loop" is what matters most.

Key Results

  • Diagnostic Accuracy: In the discovery cohort, histone-DNA complexes alone achieved an AUC of 0.8628. When combined with cfDNA and DNase activity, the AUC rose to 0.8774.
  • Validation: The combined model maintained a solid AUC of 0.7975 in the external validation cohort.
  • Risk Factors: Multivariate analysis identified three independent risk factors for PVT: high histone-DNA levels (OR 1.351), low DNase activity (OR 0.095), and low hemoglobin (OR 0.965).
  • Correlation: cfDNA levels were found to correlate strongly with total bilirubin (r = 0.84), suggesting it also tracks with the overall severity of liver failure.

Limitations and Future Work

The authors acknowledge several hurdles before this can reach the clinic:

  • Causality vs. Correlation: As an observational study, it’s unclear if the NET imbalance causes the clot or if the clot triggers the release of more NETs.
  • Etiology Specificity: The study focused almost exclusively on Chronic Hepatitis B (CHB). It remains to be seen if these markers work as well for cirrhosis caused by alcohol or fatty liver disease (NASH/MASH).
  • Sample Size: The validation cohort was relatively small (n=33). Larger, multi-center prospective trials are needed to confirm the diagnostic thresholds.
  • Therapeutic Potential: The study hints that boosting DNase activity could be a future treatment strategy to dissolve or prevent these clots, but this requires interventional testing.

Summary updated

Abstract

Imbalances in NET homeostasis are associated with PVT in CHB-related decompensated cirrhosis, including cases involving HCC. Histone-DNA complexes, a significant risk factor for PVT, show potential as a diagnostic marker for PVT in decompensated cirrhosis, particularly in HBV-related HCC.
BibTeX
@article{han2024imbalance,
  author = {Ming Han and Yujia Liu and Ying Cao and Yue Zhang and Yonghong Yan and Shuwei Deng and Xiaoxue Yuan and Huichun Xing and Yuan Huang and Liuluan Zhu},
  title = {{The Imbalance of Homeostasis in Neutrophil Extracellular Traps is Associated with Portal Vein Thrombosis in Patients with Decompensated Cirrhosis}},
  journal = {Journal of Clinical and Translational Hepatology},
  year = {2024},
  doi = {10.14218/jcth.2024.00165},
}
Figure